Her-2/neu, P-53, and their coexpression in osteosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 245-251

  Bakhshi, Sameer ^a   Gupta, Ajay ^a   Sharma, Meher C ^b   Khan, Shah Alam ^c   Rastogi, Shishir ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b Department of Pathology ^*  (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Her 2 neu; Osteosarcoma; P 53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CHILD; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; BIOPSY; BONE TUMOR; CARTILAGE CELL; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; BIOPSY; BONE NEOPLASMS; CHILD; CHONDROCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOSARCOMA; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 65349177375     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318197947e     Document Type: Article

References (48)

1. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
2. Ganjavi H, Gee M, Narendran A, et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther Cancer Gene Ther. 2006;13:415-419.
3. Ross J, Fletcher AJ, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
4. Gualberto A, Aldape K, Kozakiewicz K, et al. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA. 1998;95:5166-5171.
5. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77:71-78.
6. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/ erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.
7. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 2001;14:1277-1283.
8. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarco-ma. Cancer. 2002;94:1397-1404.
9. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarco-mas. Cancer. 2001;92:677-683.
10. Anninga JK, van de Vijver MJ, Cleton-Jansen A, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer. 2004;40:963-970.
11. Zhou H, Randall R, Brothman AR, et al. HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 2003;25:27-32.
12. George E, Niehans GA, Swanson PE, et al. Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood: an immunohistochemical investigation. Arch Pathol Lab Med. 1992;116:1033-1035.
13. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest. 2004;22:16-24.
14. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res. 2002;8:788-793.
15. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100:1936-1942.
16. Somers GR, Ho M, Zielenska M, et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 2005;8:525-532.
17. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest. 2004;84:113-121.
18. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005;41:1349-1361.
19. Carlynn WP, Holden JA, Zhou H, et al. Evaluation of HER-2/ neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med. 2006;130:691-698.
20. Kumar RV, Gupta N, Kakkar N, et al. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J Cancer Res Ther. 2006;2:20-23.
21. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 1992;52:6194-6199.
22. Wadayama B, Toguchida J, Yamaguchi T, et al. P53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer. 1993;68:1134-1139.
23. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol. 1996;122:559-565.
24. Radig K, Schneider-Stock R, Oda Y, et al. Mutation spectrum of p53 gene in highly malignant human osteosarcomas. Gen Diagn Pathol. 1996;142:25-32.
25. Mousses S, McAuley L, Bell RS, et al. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol. 1996;9:1-6.
26. Lonardo F, Ueda T, Huvos AG, et al. P53 and MDM2 alterations in osteosarcomas: correlation with clinico pathologic features and proliferative rate. Cancer. 1997;79: 1541-1547.
27. Patino-Garcia A, Sierrasesumaga L. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet. 1997;98:50-55.
28. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and meta-static osteosarcoma. Cancer. 2001;92:2181-2189.
29. Heck RK, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin. 2006;56:366-375.
30. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohis-tochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503.
31. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
32. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97: 3068-3075.
33. Chan S, Ling V. Anti-P glycoprotein antibody C219 cross reacts with cerB-2 protein: diagnostic and clinical implications. J Natl Cancer Inst. 1997;89:1473-1476.
34. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991;63:601-608.
35. Kremser R, Obrist P, Spizzo G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322-328.
36. Keshgegian AA, Cnaan A. ErbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol. 1997;108:456-463.
37. Hughes DPM, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004;64:2047-2053.
38. Witlox M, Van Beusechem V, Grill J, et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med. 2002;4: 510-516.
39. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracel-lular trafficking. Mol Biol Cell. 2001;12:1897-1910.
40. Wiley H. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res. 2003;284:78-88.
41. Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 2004;6:R24-R30.
42. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
43. Rosen PP, Lesser ML, Arroyo CD, et al. P53 in node-negative breast carcinoma: an immunohistochemical study of epide-miologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995;13:821-830.
44. Mark HFL, Brown S, Sun C-L, et al. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology. 1998;66:59-63.
45. Dressman MA, Baras A, Malinowski R, et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res. 2003;63:2194-2199.
46. Toguchida J, Ishizaki K, Nakamura Y, et al. Assignment of common allele loss in osteosarcoma to the subregion 17p13. Cancer Res. 1989;49:6247-6251.
47. Sztán M, Pápai Z, Szendrôi M, et al. Allelic losses from chromosome 17 in human osteosarcomas. Pathol Oncol Res. 1997;3:115-120.
48. Winters ZE, Leek RD, Bradburn MJ, et al. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003;5:R242-R249.